180340-69-6 Usage
General Description
6-Amino-5-bromonicotinic acid is a chemical compound with the molecular formula C6H5BrN2O2. It is a derivative of nicotinic acid and contains a bromine atom at the 5-position and an amino group at the 6-position of the nicotinic acid molecule. 6-AMINO-5-BROMONICOTINIC ACID has various potential applications in pharmaceutical and chemical industries, including as a building block for the synthesis of pharmaceutical drugs and as a precursor for the production of other organic compounds. It can also be used as an intermediate in the preparation of agrochemicals and dyes. Additionally, 6-amino-5-bromonicotinic acid may have biological activities and has been studied for its potential pharmacological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 180340-69-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,3,4 and 0 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 180340-69:
(8*1)+(7*8)+(6*0)+(5*3)+(4*4)+(3*0)+(2*6)+(1*9)=116
116 % 10 = 6
So 180340-69-6 is a valid CAS Registry Number.
InChI:InChI=1/C6H5BrN2O2/c7-4-1-3(6(10)11)2-9-5(4)8/h1-2H,(H2,8,9)(H,10,11)
180340-69-6Relevant articles and documents
FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV
-
Page/Page column 29, (2020/06/19)
The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising thes
Pyrazine derivatives as modulators of tyrosine kinases
-
, (2008/06/13)
The present invention provides pyrazine derivatives that inhibit tyrosine kinase activity. Certain pyrazine derivatives are selective inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinase. The present invention also provides pharmaceutical formulations containing the pyrazine derivatives and methods of use of these formulations as anti-tumor agents and to treat solid-tumor cancers, angiogenesis, diabetic retinopathy, rheumatoid arthritis, endometriosis and psoriasis.
TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS
-
, (2008/06/13)
-
